853O OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase II trial

J. Thariat, M. Bosset, A. Falcoz, D. Vernerey, Y. Pointreau, S. Racadot, J.C. Faivre, J. Castelli, S. Guihard, F. Huguet, S. Chapet, Y. Tao, J. Bourhis, X.S. Sun,

Annals of Oncology oct 2023, Abstract 8530,Volume 34 suppl 2, S554